Shifting the AMD Burden-Benefit Balance
Aflibercept’s newly approved administration regime permits a reduction in intravitreal injection frequency – and recent clinical trial data (ALTAIR) suggest that extended interval dosing can sustain robust vision gains over 2 years
Rod McNeil | | Longer Read
At a Glance
- The ALTAIR trial recently provided evidence to support new aflibercept treatment regimen
- Eight-weekly aflibercept dosing was associated with 96-week efficacy and safety outcomes similar to those of a monthly ranibizumab regime
- Later intervals varied from 8 to 16 weeks, the interval being adjusted on the basis of individual patient characteristics
- Treat-and-extend dosing earlier in the first year of aflibercept treatment has resulted in excellent visual outcomes, and reduced burden of treatment for many patients.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.